LTR Pharma Limited (LTP) Price & Analysis

Q: What was LTR Pharma Limited’s price range in the past 12 months?

LTR Pharma Limited lowest share price was AU$0.35 and its highest was AU$0.75 in the past 12 months.

Q: What is LTR Pharma Limited’s market cap?

LTR Pharma Limited’s market cap is AU$78.38M.

Q: When is LTR Pharma Limited’s upcoming earnings report date?

LTR Pharma Limited’s upcoming earnings report date is Mar 04, 2027 which is in 124 days.

Q: How were LTR Pharma Limited’s earnings last quarter?

LTR Pharma Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.046 earnings per share for the quarter.

Q: Is LTR Pharma Limited overvalued?

According to Wall Street analysts LTR Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does LTR Pharma Limited pay dividends?

LTR Pharma Limited does not currently pay dividends.

Q: What is LTR Pharma Limited’s EPS estimate?

LTR Pharma Limited’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does LTR Pharma Limited have?

LTR Pharma Limited has 182,274,630 shares outstanding.

Q: What happened to LTR Pharma Limited’s price movement after its last earnings report?

LTR Pharma Limited reported an EPS of -AU$0.046 in its last earnings report. Following the earnings report the stock price went down -2.083%.

Q: Which hedge fund is a major shareholder of LTR Pharma Limited?

Currently, no hedge funds are holding shares in AU:LTP

27 Followers

LTP Stock Chart & Stats

AU$0.49

<AU$0.01(1.03%)

At close: Jul 24 4:00 PM EDT

AU$0.49

<AU$0.01(1.03%)

Day’s Range― - ―

52-Week RangeAU$0.35 - AU$0.75

Previous CloseN/A

Volume154.27K

Average Volume (3M)153.30K

Market Cap

AU$78.38M

Enterprise ValueAU$79.36M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.80

Next Earnings

Mar 04, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding182,274,630

10 Day Avg. Volume101,871

30 Day Avg. Volume153,300

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

LTR Pharma Limited News

LTR Pharma advances U.S. ROXUS launch and FDA pathway for SPONTAN

An announcement from LTR Pharma Limited ( ($AU:LTP) ) is now available. LTR Pharma has begun fulfilling its...

4d ago

LTP

LTR Pharma outlines strategy and growth focus at 2026 AGM

LTR Pharma Limited ( ($AU:LTP) ) has issued an update. LTR Pharma Limited will hold its 2026 Annual...

8d ago

LTP

LTR Pharma to Test Intranasal SPONTAN in Pulmonary Arterial Hypertension Trial

The latest update is out from LTR Pharma Limited ( ($AU:LTP) ). LTR Pharma has secured ethics approval...

10d ago

LTP

LTR Pharma marks 2,000 SPONTAN units as intranasal ED spray gains traction

The latest update is out from LTR Pharma Limited ( ($AU:LTP) ). LTR Pharma has reported that more...

11d ago

LTP

LTR Pharma to Present Phase II Data and U.S. ROXUS Update in Investor Webinar

LTR Pharma Limited ( ($AU:LTP) ) has issued an announcement. LTR Pharma is positioning itself as a specialist...

26d ago

LTP

LTR Pharma Fulfils First U.S. ROXUS Prescriptions via Telehealth Channel

LTR Pharma Limited ( ($AU:LTP) ) just unveiled an update. LTR Pharma has begun fulfilling the first patient-specific...

26d ago

LTP

LTR Pharma to Showcase Clinical Data and Commercial Momentum in Upcoming Investor Webinar

The latest announcement is out from LTR Pharma Limited ( ($AU:LTP) ). LTR Pharma Limited, a commercial-stage pharmaceutical...

29d ago

LTP

LTR Pharma completes FDA pharmacokinetic dataset as SPONTAN shows rapid absorption and strong safety

The latest announcement is out from LTR Pharma Limited ( ($AU:LTP) ). LTR Pharma has released the final...

1M ago

LTP

LTR Pharma Sets October AGM as It Expands Intranasal Therapeutics Portfolio

LTR Pharma Limited ( ($AU:LTP) ) has issued an update. LTR Pharma has convened its Annual General Meeting...

1M ago

LTP

LTR Pharma Seeks ASX Quotation for Additional Shares

LTR Pharma Limited ( ($AU:LTP) ) just unveiled an announcement. LTR Pharma Limited has applied to the Australian...

2M ago

LTP

LTP FAQ

What was LTR Pharma Limited’s price range in the past 12 months?

LTR Pharma Limited lowest share price was AU$0.35 and its highest was AU$0.75 in the past 12 months.

What is LTR Pharma Limited’s market cap?

LTR Pharma Limited’s market cap is AU$78.38M.

When is LTR Pharma Limited’s upcoming earnings report date?

LTR Pharma Limited’s upcoming earnings report date is Mar 04, 2027 which is in 124 days.

How were LTR Pharma Limited’s earnings last quarter?

LTR Pharma Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.046 earnings per share for the quarter.

Is LTR Pharma Limited overvalued?

According to Wall Street analysts LTR Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does LTR Pharma Limited pay dividends?

LTR Pharma Limited does not currently pay dividends.

What is LTR Pharma Limited’s EPS estimate?

LTR Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does LTR Pharma Limited have?

LTR Pharma Limited has 182,274,630 shares outstanding.

What happened to LTR Pharma Limited’s price movement after its last earnings report?

LTR Pharma Limited reported an EPS of -AU$0.046 in its last earnings report. Following the earnings report the stock price went down -2.083%.

Which hedge fund is a major shareholder of LTR Pharma Limited?

Currently, no hedge funds are holding shares in AU:LTP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

LTR Pharma Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-54.73%

Trailing 12-Months

Asset Growth

-35.27%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

LTR Pharma Limited

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.